

Edie Weller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11395537/publications.pdf>

Version: 2024-02-01

30
papers

3,766
citations

279487

23
h-index

500791

28
g-index

30
all docs

30
docs citations

30
times ranked

3612
citing authors

#	ARTICLE	IF	CITATIONS
1	Attitudes and behaviors of physical activity in children: Findings from the Play, Lifestyle & Activity in Youth (<sc>PLAY</sc>) Questionnaire. <i>PM and R</i> , 2022, 14, 535-550.	0.9	5
2	Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. <i>Blood Advances</i> , 2022, 6, 3803-3811.	2.5	4
3	Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4-LBA4.	0.8	3
4	Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C. <i>Pediatrics</i> , 2022, 150, .	1.0	20
5	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1244-1253.	2.0	42
6	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	1.7	39
7	Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). <i>Cancer</i> , 2016, 122, 2996-3004.	2.0	31
8	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. <i>British Journal of Haematology</i> , 2015, 169, 851-858.	1.2	63
9	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. <i>British Journal of Haematology</i> , 2015, 169, 843-850.	1.2	66
10	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014, 99, 715-725.	1.7	52
11	Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients. <i>Clinical Cancer Research</i> , 2013, 19, 3640-3648.	3.2	199
12	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. <i>Blood</i> , 2011, 117, 393-402.	0.6	199
13	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	0.6	168
14	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2011, 118, 4134-4134.	0.6	0
15	Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5713-5719.	0.8	155
16	Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1607-1614.	0.8	264
17	High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties. <i>Clinical Cancer Research</i> , 2009, 15, 5829-5839.	3.2	90
18	Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma. <i>Blood</i> , 2009, 114, 1789-1789.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw. <i>Clinical Cancer Research</i> , 2008, 14, 2387-2395.	3.2	133
20	Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applicationsâ€”A Study From the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2007, 25, 805-812.	0.8	271
21	Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. <i>Blood</i> , 2007, 109, 2001-2007.	0.6	14
22	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. <i>Blood</i> , 2006, 108, 3458-3464.	0.6	494
23	Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. <i>Blood</i> , 2005, 105, 3945-3950.	0.6	94
24	Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. <i>Mayo Clinic Proceedings</i> , 2004, 79, 875-882.	1.4	120
25	Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. <i>Blood</i> , 2004, 103, 656-663.	0.6	73
26	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> , 2002, 100, 3063-3067.	0.6	759
27	Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. <i>Blood</i> , 2002, 99, 4610-4617.	0.6	78
28	T-cellâ€”depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. <i>Blood</i> , 2001, 98, 934-939.	0.6	193
29	Comparative Outcomes of T-Cellâ€”Depleted and Nonâ€”T-Cellâ€”Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion. <i>Journal of Clinical Oncology</i> , 1999, 17, 561-561.	0.8	108
30	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2725-2729.	0.6	29